BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · IEX Real-Time Price · USD
10.41
-0.15 (-1.37%)
Feb 1, 2023, 10:46 AM EST - Market open
-1.37%
Market Cap 1.94B
Revenue (ttm) 238.44M
Net Income (ttm) -193.35M
Shares Out 186.42M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 232,971
Open 10.59
Previous Close 10.55
Day's Range 10.41 - 10.62
52-Week Range 7.61 - 19.99
Beta 2.03
Analysts Buy
Price Target 16.09 (+54.64%)
Earnings Date Feb 21, 2023

About BCRX

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 in... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 3, 1994
Employees 358
Stock Exchange NASDAQ
Ticker Symbol BCRX
Full Company Profile

Financial Performance

In 2021, BCRX's revenue was $157.17 million, an increase of 782.38% compared to the previous year's $17.81 million. Losses were -$184.06 million, 0.68% more than in 2020.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for BCRX stock is "Buy." The 12-month stock price forecast is $16.09, which is an increase of 54.64% from the latest price.

Price Target
$16.09
(54.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

RESEARCH TRIANGLE PARK, N.C., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the pivotal APeX-P trial evaluating...

6 days ago - GlobeNewsWire

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to co...

1 week ago - GlobeNewsWire

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

—ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y)—

3 weeks ago - GlobeNewsWire

BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2—

3 weeks ago - GlobeNewsWire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 1...

3 weeks ago - GlobeNewsWire

Wall Street Analysts Predict a 48% Upside in BioCryst (BCRX): Here's What You Should Know

The mean of analysts' price targets for BioCryst (BCRX) points to a 47.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

3 weeks ago - Zacks Investment Research

BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 41st Annual J.P. Morgan Healthcare Co...

1 month ago - GlobeNewsWire

BioCryst (BCRX) Down as it Discontinues Developing PNH Drug

BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.

1 month ago - Zacks Investment Research

BCRX Stock Sinks as BioCryst Discontinues Drug Development

BioCryst Pharmaceuticals (NASDAQ: BCRX) stock is falling on Thursday after revealing the end of development for BCX9930. BCX9930 was in development alongside BCX10013 as a Factor D inhibitor.

1 month ago - InvestorPlace

BioCryst to discontinue development of drug

Shares of BioCryst Pharmaceuticals Inc. were down about 5% in premarket trading on Thursday after the company said it halted development of BCX9930, which was being tested as a treatment for paroxysma...

1 month ago - Market Watch

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

RESEARCH TRIANGLE PARK, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on new competitive data recently presented at the American Soc...

1 month ago - GlobeNewsWire

BioCryst to Present at JMP Securities Hematology & Oncology Summit

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present virtually at the JMP Securities Hematology &...

2 months ago - GlobeNewsWire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health

RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization fo...

2 months ago - GlobeNewsWire

BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic Therapy

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world data demonstrating rapid, sustained reduction of patient-re...

2 months ago - GlobeNewsWire

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following investor conferences:

3 months ago - GlobeNewsWire

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of 28.13% and 3.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones

—$66.0 million in ORLADEYO Q3 2022 net revenue; on-track to more than double sales in 2022 vs 2021—

3 months ago - GlobeNewsWire

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts, including one Distinguished I...

3 months ago - GlobeNewsWire

BioCryst to Report Third Quarter 2022 Financial Results on November 1

RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2022 financial results Tues...

3 months ago - GlobeNewsWire

3 Biotech Stocks to Buy Now for Extraordinary Gains

Biotech stocks have performed relatively well compared to the broader market of late. The SPDR S&P Biotech ETF (NYSEARCA: XBI) is up 21% over the past three months compared with a 6% gain for the S&P...

Other symbols: EXELVIR
4 months ago - InvestorPlace

BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer

RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. today announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing...

4 months ago - GlobeNewsWire

FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, BCX9250, for the Treatment of Fibrodysplasia Ossificans Progressiva

RESEARCH TRIANGLE PARK, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug design...

5 months ago - GlobeNewsWire

BioCryst Presents Data Demonstrating >99 Percent Suppression of Alternative Pathway Complement Activity with BCX9930 in C3G Patients

Study represents first data with BCX9930 in C3G patients Study represents first data with BCX9930 in C3G patients

5 months ago - GlobeNewsWire

U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Pandemic Influenza Preparedness

RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has exercised ...

5 months ago - GlobeNewsWire